P. Rissanen

发表

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.

A. Auvinen, C. Blomqvist, T. Saarto, 1997, British Journal of Cancer.

Adjuvant hormone therapy in breast cancer.

C. Blomqvist, I. Elomaa, P. Rissanen, 1992, Annals of medicine.

The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.

C. Blomqvist, I. Elomaa, P. Rissanen, 1992, British Journal of Cancer.

Intra‐arterial and Intravenous Use of 4′ Epidoxorubicin Combined with 5‐Fluorouracil in Primary Hepatocellular Carcinoma: A Randomized Comparison

P. Rissanen, S. Pyrhönen, P. Rissanen, 1992, American journal of clinical oncology.

FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial.

C. Blomqvist, P. Hietanen, I. Elomaa, 1992, Acta oncologica.

Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer--a randomized trial.

C. Blomqvist, I. Elomaa, P. Rissanen, 1988, Acta oncologica.

Weekly low-dose doxorubicin as second line therapy in advanced breast cancer.

C. Blomqvist, I. Elomaa, P. Rissanen, 1988, Acta oncologica.

Aminoglutethimide as second line therapy in advanced breast cancer.

C. Blomqvist, I. Elomaa, P. Rissanen, 1986, Breast cancer research and treatment.

The Steady-State Pharmacokinetics of Tamoxifen and its Metabolites in Breast Cancer Patients

P. Rissanen, I. Elomaa, P. Rissanen, 1986, The Journal of international medical research.

Primary gastrointestinal non-Hodgkin lymphoma. A review of 36 cases.

P. Rissanen, M. Kajanti, M. Karkinen-Jääskeläinen, 1988, Acta oncologica.

Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancer.

P. Virkkunen, J. Turunen, J. Halavaara, 1994, European journal of cancer.

Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapy.

C. Blomqvist, O. Alfthan, I. Elomaa, 1988, European urology.

Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.

C. Blomqvist, P. Hietanen, I. Elomaa, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial.

C. Blomqvist, T. Saarto, I. Elomaa, 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

5‐aminolaevulinic acid nanoemulsion is more effective than methyl‐5‐aminolaevulinate in daylight photodynamic therapy for actinic keratosis: a nonsponsored randomized double‐blind multicentre trial

L. Ylianttila, E. Snellman, P. Rissanen, 2019, The British journal of dermatology.

Photodynamic Therapy for Actinic Keratoses: A Randomized Prospective Non-sponsored Cost-effectiveness Study of Daylight-mediated Treatment Compared with Light-emitting Diode Treatment.

E. Snellman, P. Rissanen, N. Neittaanmäki-Perttu, 2016, Acta dermato-venereologica.

The Finnish trial of prostate cancer screening: where are we now?

A. Auvinen, M. Ruutu, M. Ala-opas, 2003, BJU international.